Psoriasis (PsO)PsOUND-PSONCT07390487
The Effects of Audio-Based Therapy on Anxiety in Psoriasis
A study testing Music Therapy and Pink Noise in people with Psoriasis (PsO) and Anxiety, run by University of California, San Francisco at 1 site in United States.
Trial summary
Anxiety in psoriasis is associated with impaired quality of life, and the prevalence of anxiety symptoms in psoriatic populations is approximately 34% and anxiety disorders up to 16%. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Psoriasis (PsO), Anxiety
- What is being tested?
- Music Therapy and Pink Noise
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 120 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Feb 2026to Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥18 years
- Self-reported dermatologist-diagnosed psoriasis
- GAD 2-Item Score ≥1 at screening
- Ability to consent and complete pre- and post-intervention surveys.
- Internet access and the ability to use a computer/smartphone with headphones for a single 23-30 minute session at home.
Who cannot join
- Severe hearing impairment precluding headphone listening
- Any condition requiring strict sound avoidance (such as seizure/epilepsy, major head trauma, severe sound-triggered migraine) that would make participation unsafe.
- Other diagnoses that in the investigator's judgment preclude safe participation or interfere with anxiety or psoriasis evaluation.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Amélie Spangenberg, Psoriasis Clinical Research Fellow, MBBS contact
United States1 site, 1 recruiting
- Recruiting
Liao Lab at UCSF
San Francisco, California, 94115
Amélie Spangenberg, Psoriasis Clinical Research Fellow, MBBS, 415-944-7618, amelie.spangenberg@ucsf.edu
Wilson Liao, MD
About this study
Anxiety in psoriasis is associated with impaired quality of life, and the prevalence of anxiety symptoms in psoriatic populations is approximately 34% and anxiety disorders up to 16%. Many experts recommend routine screening, referral, and interventions for anxiety in psoriasis; however, many barriers inhibit access to mental health resources and proper management. To our knowledge, there is a lack of easily accessible interventions that manage anxiety. Audio-based therapy offers convenient and effective interventions that show reduced anxiety in published, randomized studies and is a promising management for psoriasis patients. This study will evaluate the effects of audio therapy in patients with psoriasis and measure changes in overall symptoms.
- Conditions
- Psoriasis (PsO), Anxiety
- Being tested
- Music Therapy, Pink Noise
- Keywords
- Surveys and Questionnaires, Acoustic Stimulation, Complementary Therapies
- Medical subject headings
- Psoriasis, Anxiety Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Music TherapyBehavioural
Also called Music therapy and auditory beat stimulation (ABS), Music, Complementary Therapy, Complementary Therapies
Participants listen to the iso-principle music with added auditory beat stimulation playlist for 23-30 minutes.
Pink NoiseBehavioural
Participants listen to the pink noise playlist for 23-30 minutes.
| Study group | Role | What they receive |
|---|---|---|
| Music Therapy | Experimental | Participants listen to the iso-principle music with added auditory beat stimulation playlist for 23-30 minutes. Receives: Behavioral: Music Therapy |
| Pink Noise | Sham comparator | Participants listen to the pink noise playlist for 23-30 minutes. Receives: Behavioral: Pink Noise |
What is being measured
The primary outcome is the main question the study is designed to answer.
Anxiety: State Trait Inventory for Cognitive and Somatic Anxiety (STICSA)
The STICSA has good reliability and validity as a measure of state and trait cognitive and somatic anxiety. In this study, the post-intervention anxiety score is subtracted from the pre-intervention anxiety score, giving a measure of anxiety reduction. Greater anxiety reduction scores would indicate a better anxiety outcome.
Measured: From the pre-intervention survey to the post-intervention survey, approximately 30 minutes.
Secondary outcomes (2)
Mood: Positive and Negative Affect Scale (PANAS)
The PANAS has demonstrated good reliability and validity, and has been widely used in numerous studies to assess mood. In this study, the post-intervention PANAS scores are subtracted from the pre-intervention PANAS scores, giving a measure of positive and negative mood changes. The scale generates two scores: 1) Positive affect (higher score indicates better mood outcome) and 2) Negative affect (higher score indicates worse mood outcome).
Measured: From the pre-intervention survey to the post-intervention survey, approximately 30 minutes.
Itch: Itch Numeric Rating Score (INRS)
The INRS has good reliability and validity as a measure of 24-hour itch severity, though validity testing over more acute intervals remains limited. In this study, the post-intervention itch score is subtracted from the pre-intervention itch score, giving a measure of itch reduction. Greater itch reduction scores may indicate a better itch outcome.
Measured: From the pre-intervention survey to the post-intervention survey, approximately 30 minutes.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Feb 2026
- Study start1 Feb 2026
- Primary completionDec 2027 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (10)Papers the sponsor has linked to this study.
- Other trials for Psoriasis (PsO)Studies of the same condition, open and under way.
- More trials run by University of California, San FranciscoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of California, San Francisco
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Wilson Liao, MD, Principal investigator, University of California, San Francisco
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07390487
- Sponsor's protocol ID
- PsOUND-PSO
- Acronym
- PsOUND-PSO
- Status last verified
- Jul 2026
- First submitted
- 29 Jan 2026
- Last updated
- 23 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Yan D, Blauvelt A, Dey AK, Golpanian RS, Hwang ST, Mehta NN, Myers B, Shi ZR, Yosipovitch G, Bell S, Liao W. New Frontiers in Psoriatic Disease Research, Part II: Comorbidities and Targeted Therapies. J Invest Dermatol. 2021 Oct;141(10):2328-2337. doi: 10.1016/j.jid.2021.02.743. Epub 2021 Apr 19.
PubMed 33888321Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol. 1988 Jun;54(6):1063-70. doi: 10.1037//0022-3514.54.6.1063.
PubMed 3397865Riew GJ, Kamal K, Hijaz B, Awh KC, Nambudiri VE. Clinical music interventions and music therapy in dermatology. Arch Dermatol Res. 2023 Nov;315(9):2485-2490. doi: 10.1007/s00403-023-02634-1. Epub 2023 May 19.
PubMed 37208459Mallik A, Russo FA. The effects of music & auditory beat stimulation on anxiety: A randomized clinical trial. PLoS One. 2022 Mar 9;17(3):e0259312. doi: 10.1371/journal.pone.0259312. eCollection 2022.
PubMed 35263341Jalenques I, Bourlot F, Martinez E, Pereira B, D'Incan M, Lauron S, Rondepierre F. Prevalence and Odds of Anxiety Disorders and Anxiety Symptoms in Children and Adults with Psoriasis: Systematic Review and Meta-analysis. Acta Derm Venereol. 2022 Aug 26;102:adv00769. doi: 10.2340/actadv.v102.1386.
PubMed 35604236Hedemann TL, Liu X, Kang CN, Husain MI. Associations between psoriasis and mental illness: an update for clinicians. Gen Hosp Psychiatry. 2022 Mar-Apr;75:30-37. doi: 10.1016/j.genhosppsych.2022.01.006. Epub 2022 Jan 25.
PubMed 35101785Gros DF, Antony MM, Simms LJ, McCabe RE. Psychometric properties of the State-Trait Inventory for Cognitive and Somatic Anxiety (STICSA): comparison to the State-Trait Anxiety Inventory (STAI). Psychol Assess. 2007 Dec;19(4):369-81. doi: 10.1037/1040-3590.19.4.369.
PubMed 18085930Phan NQ, Blome C, Fritz F, Gerss J, Reich A, Ebata T, Augustin M, Szepietowski JC, Stander S. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol. 2012 Sep;92(5):502-7. doi: 10.2340/00015555-1246.
PubMed 22170091Gray EK, Watson, D. Assessing positive and negative affect via self-report. In: Coan JA, Allen, J.J.B., editor. Handbook of emotion elicitation and assessment. New York, NY: Oxford University Press; 2007.
Bados A, Gomez-Benito J, Balaguer G. The state-trait anxiety inventory, trait version: does it really measure anxiety? J Pers Assess. 2010 Nov;92(6):560-7. doi: 10.1080/00223891.2010.513295.
PubMed 20954057
Study at a glance
From the registry record, last updated by the sponsor on 23 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effects of Audio-Based Therapy on Anxiety in Psoriasis
- ClinicalTrials.gov ID
- NCT07390487
- Acronym / sponsor ID
- PsOUND-PSO / PsOUND-PSO
- Conditions
- Psoriasis (PsO), Anxiety
- Keywords
- Surveys and Questionnaires, Acoustic Stimulation, Complementary Therapies
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- University of California, San FranciscoUniversity, hospital or other
- Study start
- 1 Feb 2026 (actual)
- Primary completion
- Dec 2027 (estimated)
- Study completion
- Dec 2027 (estimated)
- First posted
- 5 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Anxiety in psoriasis is associated with impaired quality of life, and the prevalence of anxiety symptoms in psoriatic populations is approximately 34% and anxiety disorders up to 16%. Many experts recommend routine screening, referral, and interventions for anxiety in psoriasis; however, many barriers inhibit access to mental health resources and proper management. To our knowledge, there is a lack of easily accessible interventions that manage anxiety. Audio-based therapy offers convenient and effective interventions that show reduced anxiety in published, randomized studies and is a promising management for psoriasis patients. This study will evaluate the effects of audio therapy in patients with psoriasis and measure changes in overall symptoms.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Music Therapy | Experimental | Behavioral: Music TherapyParticipants listen to the iso-principle music with added auditory beat stimulation playlist for 23-30 minutes. |
| Pink Noise | Sham comparator | Behavioral: Pink NoiseParticipants listen to the pink noise playlist for 23-30 minutes. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Age ≥18 years
- Self-reported dermatologist-diagnosed psoriasis
- GAD 2-Item Score ≥1 at screening
- Ability to consent and complete pre- and post-intervention surveys.
- Internet access and the ability to use a computer/smartphone with headphones for a single 23-30 minute session at home.
Key exclusion criteria (3 listed)
- Severe hearing impairment precluding headphone listening
- Any condition requiring strict sound avoidance (such as seizure/epilepsy, major head trauma, severe sound-triggered migraine) that would make participation unsafe.
- Other diagnoses that in the investigator's judgment preclude safe participation or interfere with anxiety or psoriasis evaluation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Music TherapyAlso: Music therapy and auditory beat stimulation (ABS), Music, Complementary Therapy, Complementary TherapiesParticipants listen to the iso-principle music with added auditory beat stimulation playlist for 23-30 minutes. | Behavioural | Music Therapy |
| Pink NoiseParticipants listen to the pink noise playlist for 23-30 minutes. | Behavioural | Pink Noise |
Primary outcome
Anxiety: State Trait Inventory for Cognitive and Somatic Anxiety (STICSA)
Time frame: From the pre-intervention survey to the post-intervention survey, approximately 30 minutes.
The STICSA has good reliability and validity as a measure of state and trait cognitive and somatic anxiety. In this study, the post-intervention anxiety score is subtracted from the pre-intervention anxiety score, giving a measure of anxiety reduction. Greater anxiety reduction scores would indicate a better anxiety outcome.
2 secondary outcomes
Mood: Positive and Negative Affect Scale (PANAS)
Time frame: From the pre-intervention survey to the post-intervention survey, approximately 30 minutes.
Itch: Itch Numeric Rating Score (INRS)
Time frame: From the pre-intervention survey to the post-intervention survey, approximately 30 minutes.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jul 2026.
- Background: PubMed 33888321Yan D, Blauvelt A, Dey AK, Golpanian RS, Hwang ST, Mehta NN, Myers B, Shi ZR, Yosipovitch G, Bell S, Liao W. New Frontiers in Psoriatic Disease Research, Part II: Comorbidities and Targeted Therapies. J Invest Dermatol. 2021 Oct;141(10):2328-2337. doi: 10.1016/j.jid.2021.02.743. Epub 2021 Apr 19.
- Background: PubMed 3397865Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol. 1988 Jun;54(6):1063-70. doi: 10.1037//0022-3514.54.6.1063.
- Background: PubMed 37208459Riew GJ, Kamal K, Hijaz B, Awh KC, Nambudiri VE. Clinical music interventions and music therapy in dermatology. Arch Dermatol Res. 2023 Nov;315(9):2485-2490. doi: 10.1007/s00403-023-02634-1. Epub 2023 May 19.
- Background: PubMed 35263341Mallik A, Russo FA. The effects of music & auditory beat stimulation on anxiety: A randomized clinical trial. PLoS One. 2022 Mar 9;17(3):e0259312. doi: 10.1371/journal.pone.0259312. eCollection 2022.
- Background: PubMed 35604236Jalenques I, Bourlot F, Martinez E, Pereira B, D'Incan M, Lauron S, Rondepierre F. Prevalence and Odds of Anxiety Disorders and Anxiety Symptoms in Children and Adults with Psoriasis: Systematic Review and Meta-analysis. Acta Derm Venereol. 2022 Aug 26;102:adv00769. doi: 10.2340/actadv.v102.1386.
- Background: PubMed 35101785Hedemann TL, Liu X, Kang CN, Husain MI. Associations between psoriasis and mental illness: an update for clinicians. Gen Hosp Psychiatry. 2022 Mar-Apr;75:30-37. doi: 10.1016/j.genhosppsych.2022.01.006. Epub 2022 Jan 25.
- Background: PubMed 18085930Gros DF, Antony MM, Simms LJ, McCabe RE. Psychometric properties of the State-Trait Inventory for Cognitive and Somatic Anxiety (STICSA): comparison to the State-Trait Anxiety Inventory (STAI). Psychol Assess. 2007 Dec;19(4):369-81. doi: 10.1037/1040-3590.19.4.369.
- Background: PubMed 22170091Phan NQ, Blome C, Fritz F, Gerss J, Reich A, Ebata T, Augustin M, Szepietowski JC, Stander S. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol. 2012 Sep;92(5):502-7. doi: 10.2340/00015555-1246.
- BackgroundGray EK, Watson, D. Assessing positive and negative affect via self-report. In: Coan JA, Allen, J.J.B., editor. Handbook of emotion elicitation and assessment. New York, NY: Oxford University Press; 2007.
- Background: PubMed 20954057Bados A, Gomez-Benito J, Balaguer G. The state-trait anxiety inventory, trait version: does it really measure anxiety? J Pers Assess. 2010 Nov;92(6):560-7. doi: 10.1080/00223891.2010.513295.
- Individual participant dataSharing planned: No
Related trials for Psoriasis (PsO)
RecruitingPhase 4
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
Psoriasis, Overweight or Obesity
RecruitingPhase 1
A Study of HL40626S Tablets in Healthy Adults
Skin Disease, Immune System Disease
RecruitingPhase 3
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
Plaque Psoriasis
Not yet recruiting
Definition of Novel Optoacoustic Biomarkers of Psoriasis and Psoriatic Arthritis
Psoriasis (PsO), Psoriasis Arthritis
Not yet recruitingObservational study
A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy
Plaque Psoriasis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Amélie Spangenberg, Psoriasis Clinical Research Fellow, MBBS contact
Wilson Liao, MD principal investigator
University of California, San Francisco
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Music Therapy and Pink Noise in people with Psoriasis (PsO) and Anxiety, run by University of California, San Francisco at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 23 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Amélie Spangenberg, Psoriasis Clinical Research Fellow, MBBS (415-944-7618, amelie.spangenberg@ucsf.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Anxiety: State Trait Inventory for Cognitive and Somatic Anxiety (STICSA) (time frame: From the pre-intervention survey to the post-intervention survey, approximately 30 minutes.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07390487, which also lists 10 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jul 2026.